India, April 29 -- In a key development reinforcing its leadership in the Indian pharmaceutical landscape,Morepen Laboratorieshas got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization(CDSCO)to conductBioequivalence (BE) studiesforResmetirom60 mg, 80 mg and 100 mg tablets as per the protocol submitted.This will be followed by clinical trials as per approved protocols.

Resmetirom is a highly promising therapy under development for non-alcoholic steatohepatitis(NASH), a serious form of non-alcoholic fatty liver disease(NAFLD)characterised byinflammation, liver damage, and fat accumulation in the liver, potentially leading to scarring (fibrosis), cirrhosis, and even liver cancer.It is often associat...